Recent 8-K filings for UTHR

• August 5, 2026, 6:33 AM ET earnings materiality 0.70 neutral item 2.02item 9.01

  United Therapeutics Reports Q2 2026 Revenue of $783.3M, Net Income Up 8% to $333M

  Total revenues decreased 2% year-over-year to $783.3M; net income rose 8% to $333.0M.

• May 6, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  UTHR Q1 revenue falls 2% to $781.5M; net income down 15%; $2B buyback

  Total revenues $781.5M (-2% YoY); net income $274.9M (-15%); diluted EPS $5.82 vs $6.63.

• March 30, 2026, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  United Therapeutics' TETON-1 Tyvaso meets primary endpoint; FVC improvement 130.1 mL (p<0.0001)

  TETON-1 met primary endpoint: change in absolute FVC by 130.1 mL vs placebo (p<0.0001) at week 52.

• March 9, 2026, 7:59 PM ET other material materiality 0.75 positive item 1.01item 7.01item 9.01 ◈ Material Agreements ×2

  United Therapeutics authorizes $2B buyback, enters $1.5B accelerated share repurchase with Citi

  Board approves up to $2B stock repurchase program through March 9, 2027.

• March 2, 2026, 6:59 PM ET other material materiality 0.85 positive item 7.01item 9.01

  United Therapeutics' ralinepag phase 3 meets primary endpoint; 55% risk reduction in PAH clinical worsening

  Ralinepag reduced risk of clinical worsening by 55% vs placebo (HR 0.45, p<0.0001) in phase 3 ADVANCE OUTCOMES study.

• February 25, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  United Therapeutics reports record $3.18B FY2025 revenue; EPS $27.86 diluted

  FY 2025 revenue hit record $3.18B (+11% YoY); net income $1.33B ($27.86 diluted EPS) vs $1.20B ($24.64) in 2024.

• October 29, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  United Therapeutics reports record Q3 revenue $799.5M (+7% YoY); EPS $7.16 diluted, TETON-2 breakthrough

  Revenue $799.5M (+7% YoY); net income $338.7M (+10%); diluted EPS $7.16 vs $6.39.

• September 2, 2025, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  United Therapeutics' Tyvaso succeeds in TETON-2 IPF study, shows 95.6mL FVC improvement

  TETON-2 met primary endpoint: Tyvaso improved absolute FVC by 95.6 mL vs placebo at week 52 (p<0.0001).

• August 1, 2025, 7:59 PM ET other material materiality 0.75 positive item 1.01item 7.01item 9.01

  United Therapeutics enters $1B accelerated share repurchase agreements with Citibank

  Two ASR agreements with Citibank: $500M uncollared and $500M collared; total upfront payment $1B due Aug 4, 2025.

• July 30, 2025, 7:59 PM ET earnings materiality 0.90 positive item 2.02item 9.01

  United Therapeutics Reports Record Q2 2025 Revenue of $798.6M, Authorizes $1B Buyback

  Record total revenue of $798.6 million, up 12% year-over-year, driven by Tyvaso DPI growth of 22% to $315 million.

• April 30, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  United Therapeutics reports record Q1 revenue of $794.4M, up 17% YoY, EPS $6.63

  Total revenues $794.4M (+17% YoY); net income $322.2M (+5%); diluted EPS $6.63 (+7% from $6.17).

• February 26, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  United Therapeutics reports record $2.88B revenue in FY2024, up 24% YoY

  Q4 revenue $735.9M (+20% YoY); net income $301.3M vs $217.1M in Q4 2023.

• October 30, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  United Therapeutics Q3 revenue $748.9M (+23% YoY); net income $309.1M (+16%)

  Total revenues $748.9M, +23% YoY; net income $309.1M ($6.39 diluted EPS) vs $267.6M ($5.38).

• July 31, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  United Therapeutics Q2 2024 revenue up 20% to $714.9M, EPS $5.85

  Total revenues $714.9M (+20% YoY); net income $278.1M ($5.85 diluted EPS) vs $259.2M ($5.24) in Q2 2023.

• May 1, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  United Therapeutics Q1 2024 revenue up 34% to $677.7M; net income $306.6M

  Total revenues $677.7M (+34% YoY); Tyvaso product line grew 56% to $372.5M.

• March 25, 2024, 7:59 PM ET other material materiality 0.75 positive item 1.01item 7.01item 9.01 ◈ Material Agreements

  United Therapeutics authorizes $1B accelerated share repurchase with Citibank

  Board authorized up to $1B of common stock repurchase; ASR agreement signed with Citibank.

• February 27, 2024, 6:59 PM ET litigation materiality 0.75 neutral item 8.01

  United Therapeutics moves to block Liquidia's PH-ILD product with preliminary injunction and FDA suit

  Filed preliminary injunction motion in Delaware on Feb 26, 2024, alleging Liquidia's PH-ILD product infringes U.S. Patent No. 11,826,327 (expires 2042).

• February 21, 2024, 6:59 PM ET other material materiality 0.70 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases ×2

  United Therapeutics reports record $2.33B 2023 revenue (+20% YoY); sues FDA over Liquidia NDA amendment

  FY 2023 revenue $2.33B, net income $984.8M ($19.81 diluted EPS).

• December 20, 2023, 6:59 PM ET litigation materiality 0.85 negative item 8.01

  Federal Circuit cancels key Tyvaso patent; Liquidia may launch Yutrepia sooner

  Court affirmed IPR decision canceling claims of U.S. Patent No. 10,716,793 covering Tyvaso and Tyvaso DPI.

• November 1, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  United Therapeutics Q3 revenue $609.4M (+18% YoY), net income $267.6M

  Total revenues $609.4M (+18% YoY); net income $267.6M ($5.38 diluted EPS) vs $239.3M ($4.91) Q3 2022.

• August 2, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  United Therapeutics Q2 2023: revenue $596.5M (+28%), net income $259.2M (+123%)

  Total revenues $596.5M (+28% YoY), net income $259.2M (+123%), diluted EPS $5.24.

• July 24, 2023, 7:59 PM ET litigation materiality 0.75 positive item 8.01item 9.01

  United Therapeutics wins Federal Circuit appeal in Liquidia patent litigation; Yutrepia approval delayed

  Federal Circuit affirmed Liquidia's Yutrepia infringes United Therapeutics' '793 patent; FDA approval blocked until patent expires May 14, 2027.

• May 3, 2023, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01 ◈ Earnings Releases

  United Therapeutics Q1 revenue $506.9M (+10% YoY); Tyvaso sales up 39%

  Net income $240.9M flat YoY; diluted EPS $4.86 vs $5.03.

• February 22, 2023, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  United Therapeutics reports record 2022 revenue of $1.94B, up 15% YoY; Q4 EPS $2.67

  Full year total revenues $1.94B, up 15% YoY; net income $727.3M ($15.00 diluted EPS).

• November 2, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  United Therapeutics Q3 revenue $516M (+16% YoY); net income $239M (+47%)

  Net income per diluted share $4.91; Tyvaso revenues $257.7M (+57% YoY) driven by Tyvaso DPI launch.

• September 20, 2022, 7:59 PM ET other material materiality 0.65 negative item 8.01

  United Therapeutics terminates PERFECT study of Tyvaso for PH associated with COPD

  DSMC recommended termination after routine safety and efficacy analysis.

• September 1, 2022, 7:59 PM ET litigation materiality 0.90 positive item 8.01item 9.01

  Court rules Liquidia's Yutrepia infringes United Therapeutics patent; injunction expected through 2027

  District Court finds Liquidia would induce infringement of '793 patent claims; claims not invalid.

• August 3, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  United Therapeutics Q2 2022 revenue up 5% to $466.9M; net income down 33%

  Total revenues $466.9M (+5% YoY); net income $116.0M ($2.41 diluted EPS) vs $172.6M ($3.65) in Q2 2021.

• May 24, 2022, 7:59 PM ET regulatory materiality 0.80 positive item 8.01item 9.01

  FDA approves United Therapeutics' Tyvaso DPI for PAH and PH-ILD; launch underway

  FDA approved Tyvaso DPI (treprostinil inhalation powder) for PAH (WHO Group 1) and PH-ILD (WHO Group 3).

• May 4, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  United Therapeutics Q1 revenue up 22% to $461.9M; diluted EPS $5.03 vs $0.61 YoY

  Q1 revenue $461.9M (+22% YoY) driven by Tyvaso ($172M, +40%) and Unituxin ($55.6M, +27%) on label expansion and Japan launch.

• April 22, 2022, 7:59 PM ET regulatory materiality 0.75 positive item 8.01

  CMS expands Tyvaso coverage to include PH-ILD; effective June 5, 2022

  CMS updated Local Coverage Determination for Tyvaso (treprostinil) to include pulmonary hypertension associated with interstitial lung disease.

• April 1, 2022, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 1.02item 2.03item 9.01

  United Therapeutics enters $2B credit agreement, draws $800M to refinance existing debt

  New $2B unsecured revolving credit facility with $1.2B Tranche A and $800M Tranche B; can be increased by up to $500M.

• February 24, 2022, 6:59 PM ET earnings materiality 0.85 neutral item 2.02item 9.01

  United Therapeutics FY2021 revenue $1.69B (+14% YoY); Tyvaso DPI decision pushed to May 2022

  Full year 2021 revenue $1.69B, up 14% YoY; Q4 revenue $415M, up 8% YoY.

• January 18, 2022, 6:59 PM ET regulatory materiality 0.75 positive item 8.01

  FDA accepts United Therapeutics' resubmitted NDA for Tyvaso DPI as Class 1 review; target date Feb 2022

  FDA accepted resubmission of NDA for Tyvaso DPI as a Class 1 response after Complete Response Letter in Oct 2021.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event earnings

26 positive 3 negative 21 neutral

source · UTHR on sec.gov